Gelteq begins veterinary clinical trial for antiparasitic drug candidate
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Gelteq Commences Veterinary Medicine Clinical Trial to Support an FDA Regulatory Pathway
May 20, 2026 8:00 AM EDTMELBOURNE, Australia, May 20, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (Gelteq) today announced the commencement of its first clinical trial for an antiparasitic drug candidate powered by Gelteq® technology, marking a significant milestone as the Company expands into the veterinary pharmaceutical sector.
The clinical trial seeks to support Gelteqs planned FDA regulatory pathway for animal use, with the Company targeting a potential application later in 2026.
This clinical trial represents a significant milestone for Gelteq as we expand into the veterinary pharmaceutical market, said Nathan Givoni, CEO of Gelteq. Building on our prior regulatory progress with the FDA, we are now advancing a... More
